<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int Semin Surg Oncol</journal-id><journal-title>International Seminars in Surgical Oncology : ISSO</journal-title><issn pub-type="epub">1477-7800</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19203387</article-id><article-id pub-id-type="pmc">2647547</article-id><article-id pub-id-type="publisher-id">1477-7800-6-5</article-id><article-id pub-id-type="doi">10.1186/1477-7800-6-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Current indications for post-mastectomy radiation</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Vilarino-Varela</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mariavilarino@yahoo.co.uk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Chin</surname><given-names>Yaw Sinn</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>yawschin@yahoo.com.au</email></contrib><contrib id="A3" corresp="yes" contrib-type="author"><name><surname>Makris</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>amakris@nhs.net</email></contrib></contrib-group><aff id="I1"><label>1</label>Academic Oncology Unit, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK</aff><aff id="I2"><label>2</label>Cancer Care Centre, St. George Hospital, Short Street, Kogarah, NSW 2217, Australia</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>9</day><month>2</month><year>2009</year></pub-date><volume>6</volume><fpage>5</fpage><lpage>5</lpage><ext-link ext-link-type="uri" xlink:href="http://www.issoonline.com/content/6/1/5"/><history><date date-type="received"><day>25</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>9</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Vilarino-Varela et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Vilarino-Varela et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>               Vilarino-Varela               Maria                              mariavilarino@yahoo.co.uk            </dc:author><dc:title>            Current indications for post-mastectomy radiation         </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>International Seminars in Surgical Oncology 6(1): 5-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1477-7800(2009)6:1&#x0003c;5&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1477-7800</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>It has been long established that post-mastectomy radiotherapy reduces the risk of locoregional failure. A survival advantage, however, has only recently been demonstrated. We here provide a review of the literature as regards to the current indications for post-mastectomy radiotherapy.</p></abstract></article-meta></front><body><sec><title>Current indications for post-mastectomy radiation</title><p>Primary breast carcinoma may be managed surgically with either mastectomy or breast conserving surgery. Although radiotherapy following breast conserving surgery is widely accepted, the role of post-mastectomy radiotherapy (PMRT) has been a subject for debate for many years. PMRT has been known since the 1970's to substantially reduce the risk of locoregional failure (LRF), however, a disease specific survival and overall survival advantage has only more recently been demonstrated [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. The systemic therapy of breast cancer has also evolved since many of the studies were conducted, raising the issue of how best to incorporate PMRT into current clinical practice.</p><p>Randomized control studies of PMRT have consistently reported improved rates of locoregional control by two-thirds regardless of patient characteristics such as age, treatment era or disease characteristics [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Only in the late 1990's was it noted that PMRT conveyed a survival advantage in high risk patients treated with adjuvant chemotherapy or hormonal therapy [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. The Danish 82b study of PMRT in premenopausal women receiving adjuvant CMF chemotherapy reported a reduction in LRF (9% v. 32%, p &#x0003c; 0.001) and improved 10 year overall survival (54% v. 45%, p &#x0003c; 0.001) in patients receiving PMRT [<xref ref-type="bibr" rid="B2">2</xref>] with similar results reported in the British Columbia study [<xref ref-type="bibr" rid="B1">1</xref>]. The Danish 82c study assessing PMRT in postmenopausal women receiving one year adjuvant tamoxifen also revealed similar reductions in LRF (8% v. 35%, p &#x0003c; 0.001) and improved 10 year overall survival (45% v. 36%, p = 0.03) [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>There are a number of reasons why a survival advantage may not have initially been apparent. Original studies were conducted in the era prior to adjuvant systemic therapy. The resulting reduction of distant failure with systemic therapy may allow the survival effect of PMRT to be more evident. Analysis of cause-specific mortality in the older PMRT studies revealed that the reduction in breast cancer deaths was cancelled out by an increase in late cardiac mortality secondary to radiotherapy [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. With modern radiotherapy techniques delivery of dose to the chest wall is more uniform and cardiac dose minimized. Older studies were also not stratified according to risk and being of small sample size not powered sufficiently to detect a small survival advantage.</p><p>The absolute benefit gained from PMRT is believed greatest for those at high risk of LRF. There is consensus that PMRT should be considered when risk of LRF is greater than 20%, such as for patients with four or more positive axillary lymph nodes, primary tumour size 5 cm or more, T4 disease and positive/very close margin [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. PMRT is not indicated in patients with tumours less than 5 cm in size and negative axillary nodes as there is only small benefit in terms of locoregional control, and insignificant absolute survival advantage. Several studies have suggested other factors that may contribute to risk of LRF particularly when present in combination [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. These include age less than 40 years, histological grade 3 tumours, presence of lymphovascular invasion, less than 6 nodes removed at axillary dissection and significant nodal extracapsular spread (&#x0003e; 2 mm). The merit of PMRT, however, in this group of patients is not known.</p><p>It remains unclear whether patients with one to three axillary nodes positive benefit significantly from PMRT. A number of collaborative groups (including the Eastern Cooperative Oncology Group, the International Breast Cancer Study Group and the National Surgical Adjuvant Breast and Bowel Project) have reported patterns of LRF following mastectomy in a number of their trials and have reported that this group of patients experience a LRF rate of 13&#x02013;19% compared with 30&#x02013;33% as reported in the key randomised trials [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. This discrepancy may be explained by limited axillary dissection underestimating the true extent of axillary nodal involvement as only a median of 7 axillary nodes were removed in the Danish study and 11 nodes in the British Columbia study compared with 15&#x02013;17 nodes in these other studies (which were not directly investigating the value of PMRT). A subset analysis of the Danish 82 b and c studies has been performed including only those with 8 or more axillary nodes removed reporting continued significant and equal reductions in LRF and overall survival at 15 years with PMRT in both the one to three and greater than four involved node groups[<xref ref-type="bibr" rid="B4">4</xref>]. LRF, however, remained high in the subgroup analysed and the caveat remains that the extent of adjuvant systemic therapy received in the Danish studies was less than current clinical practice which may affect the perceived benefit of PMRT in this group. To resolve whether patients with one to three positive axillary nodes should undergo PMRT a phase III randomised control trial &#x02013; the Selective Use of Post-operative Radiotherapy after Mastectomy (SUPREMO) trial &#x02013; is currently being conducted in Europe randomising patients with tumours less than 5 cm in size and 0&#x02013;3 positive axillary nodes.</p><p>The commonest site of LRF following mastectomy and axillary nodal dissection is the chest wall (50&#x02013;75%) followed by the supraclavicular fossa and infraclavicular region (20&#x02013;40%) [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. The rate of axillary recurrence following a level I/II axillary dissection is &#x0003c; 5% at 10 years [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>] and as such the axilla is not routinely irradiated as part of PMRT. Furthermore, irradiating the entire axilla following axillary dissection would significantly increase the rate of chronic arm morbidity and lymphoedema [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>].</p><p>Irradiation of the internal mammary nodal region remains controversial. Clinical evidence of recurrence at this site appears uncommon [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>] despite older surgical reports suggesting high rates of involvement [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. The Danish and British Columbia studies incorporated internal mammary nodal irradiation [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>] but its contribution to survival is unclear. There remains a particular concern regarding radiation dose to the heart from treatment of the internal mammary chain and thereby increased risk of late cardiac toxicity. Results from the European Organisation for Research and Treatment of Cancer (EORTC) 22922 and the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) MA20 randomised trials may provide further clarification.</p><p>Systemic therapy of early breast cancer has evolved considerably since many of the PMRT studies were conducted. Women are more likely to receive more cardiotoxic adjuvant systemic therapy. There is a significant survival advantage to anthracyline based regimens compared to CMF [<xref ref-type="bibr" rid="B18">18</xref>], and as a result anthracyclines are now routinely incorporated into most adjuvant chemotherapy schedules. High risk patients may also receive taxanes following evidence of a further survival advantage when added to anthracyclines [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. Furthermore, recent studies have demonstrated a survival benefit from the addition of trastuzumab in patients with HER2-positive tumours [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. The potential cardiotoxicity of trastuzumab is now well-established. Whether PMRT offers a further advantage in patients receiving optimal systemic adjuvant therapy is unclear. However, the MD Anderson Cancer Center and the NSABP series assessing locoregional recurrence in patients receiving anthracycline based chemotherapy suggest that locoregional failure remains an important concern [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. The current recommended duration of adjuvant hormonal therapy is 5 years, compared to one as in the Danish 82c study, which may also have an impact on LRF. Furthermore, in postmenopausal women, the aromatase inhibitors (AIs) are increasingly being used instead of tamoxifen. AIs have been shown to reduce both local and distal relapse compared to tamoxifen [<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B26">26</xref>].</p></sec><sec><title>Conclusion</title><p>PMRT reduces the risk of LRF and increases overall survival in high risk patients. Current indications for PMRT include axillary nodal involvement of 4 or more nodes, disease 5 cm or more in size, T4 disease and positive surgical margins. The potential benefits of PMRT in patients with &#x0003c; 4 positive axillary nodes remain controversial and recruitment to ongoing clinical trials should be encouraged.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>MVV performed literature search, reviewed literature and drafted manuscript. YSC assisted literature search and in drafting of manuscript. AM proposed the review, revised manuscript critically for intellectual content. All authors read and approved the final manuscript</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ragaz</surname><given-names>J</given-names></name><name><surname>Jackson</surname><given-names>SM</given-names></name><name><surname>Le</surname><given-names>N</given-names></name><name><surname>Plenderleith</surname><given-names>IH</given-names></name><name><surname>Spinelli</surname><given-names>JJ</given-names></name><name><surname>Basco</surname><given-names>VE</given-names></name><name><surname>Wilson</surname><given-names>KS</given-names></name><name><surname>Knowling</surname><given-names>MA</given-names></name><name><surname>Coppin</surname><given-names>CM</given-names></name><name><surname>Paradis</surname><given-names>M</given-names></name><name><surname>Coldman</surname><given-names>AJ</given-names></name><name><surname>Olivotto</surname><given-names>IA</given-names></name></person-group><article-title>Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer</article-title><source>N Engl J Med</source><year>1997</year><volume>337</volume><fpage>956</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">9309100</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199710023371402</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Overgaard</surname><given-names>M</given-names></name><name><surname>Hansen</surname><given-names>PS</given-names></name><name><surname>Overgaard</surname><given-names>J</given-names></name><name><surname>Rose</surname><given-names>C</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Bach</surname><given-names>F</given-names></name><name><surname>Kjaer</surname><given-names>M</given-names></name><name><surname>Gadeberg</surname><given-names>CC</given-names></name><name><surname>Mouridsen</surname><given-names>HT</given-names></name><name><surname>Jensen</surname><given-names>MB</given-names></name><name><surname>Zedeler</surname><given-names>K</given-names></name></person-group><article-title>Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial</article-title><source>N Engl J Med</source><year>1997</year><volume>337</volume><fpage>949</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">9395428</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199710023371401</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Overgaard</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>MB</given-names></name><name><surname>Overgaard</surname><given-names>J</given-names></name><name><surname>Hansen</surname><given-names>PS</given-names></name><name><surname>Rose</surname><given-names>C</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Kamby</surname><given-names>C</given-names></name><name><surname>Kjaer</surname><given-names>M</given-names></name><name><surname>Gadeberg</surname><given-names>CC</given-names></name><name><surname>Rasmussen</surname><given-names>BB</given-names></name><name><surname>Blichert-Toft</surname><given-names>M</given-names></name><name><surname>Mouridsen</surname><given-names>HT</given-names></name></person-group><article-title>Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>1641</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10335782</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(98)09201-0</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Overgaard</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>HM</given-names></name><name><surname>Overgaard</surname><given-names>J</given-names></name></person-group><article-title>Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&#x00026;c randomized trials</article-title><source>Radiother Oncol</source><year>2007</year><volume>82</volume><fpage>247</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">17306393</pub-id><pub-id pub-id-type="doi">10.1016/j.radonc.2007.02.001</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>TJ</given-names></name><name><surname>Julian</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Jadad</surname><given-names>AR</given-names></name><name><surname>Levine</surname><given-names>ML</given-names></name></person-group><article-title>Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>1220</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10715291</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>H</given-names></name><name><surname>Rutqvist</surname><given-names>L</given-names></name><name><surname>Houghton</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>R</given-names></name><name><surname>Redmond</surname><given-names>C</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>Baum</surname><given-names>M</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name><name><surname>Host</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy</article-title><source>J Clin Oncol</source><year>1994</year><volume>12</volume><fpage>447</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">8120544</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><article-title>Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1757</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">10832826</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02263-7</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Recht</surname><given-names>A</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>Davidson</surname><given-names>NE</given-names></name><name><surname>Fowble</surname><given-names>BL</given-names></name><name><surname>Solin</surname><given-names>LJ</given-names></name><name><surname>Cummings</surname><given-names>FJ</given-names></name><name><surname>Falkson</surname><given-names>G</given-names></name><name><surname>Falkson</surname><given-names>HC</given-names></name><name><surname>Taylor</surname><given-names>SG</given-names><suffix>4th</suffix></name><name><surname>Tormey</surname><given-names>DC</given-names></name></person-group><article-title>Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>1689</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">10561205</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Strom</surname><given-names>EA</given-names></name><name><surname>Buchholz</surname><given-names>TA</given-names></name><name><surname>Thames</surname><given-names>HD</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name><name><surname>Jhingran</surname><given-names>A</given-names></name><name><surname>Hortobagyi</surname><given-names>G</given-names></name><name><surname>Buzdar</surname><given-names>AU</given-names></name><name><surname>Theriault</surname><given-names>R</given-names></name><name><surname>Singletary</surname><given-names>SE</given-names></name><name><surname>McNeese</surname><given-names>MD</given-names></name></person-group><article-title>Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2817</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">10920129</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wallgren</surname><given-names>A</given-names></name><name><surname>Bonetti</surname><given-names>M</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>Castiglione-Gertsch</surname><given-names>M</given-names></name><name><surname>Holmberg</surname><given-names>SB</given-names></name><name><surname>Lindtner</surname><given-names>J</given-names></name><name><surname>Th&#x000fc;rlimann</surname><given-names>B</given-names></name><name><surname>Fey</surname><given-names>M</given-names></name><name><surname>Werner</surname><given-names>ID</given-names></name><name><surname>Forbes</surname><given-names>JF</given-names></name><name><surname>Price</surname><given-names>K</given-names></name><name><surname>Coates</surname><given-names>AS</given-names></name><name><surname>Collins</surname><given-names>J</given-names></name><collab>International Breast Cancer Study Group Trials I through VII</collab></person-group><article-title>Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>1205</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">12663706</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2003.03.130</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taghian</surname><given-names>A</given-names></name><name><surname>Jeong</surname><given-names>JH</given-names></name><name><surname>Mamounas</surname><given-names>E</given-names></name><name><surname>Anderson</surname><given-names>S</given-names></name><name><surname>Bryant</surname><given-names>J</given-names></name><name><surname>Deutsch</surname><given-names>M</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name></person-group><article-title>Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>4247</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">15452182</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2004.01.042</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strom</surname><given-names>EA</given-names></name><name><surname>Woodward</surname><given-names>WA</given-names></name><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Buchholz</surname><given-names>TA</given-names></name><name><surname>Perkins</surname><given-names>GH</given-names></name><name><surname>Jhingran</surname><given-names>A</given-names></name><name><surname>Theriault</surname><given-names>R</given-names></name><name><surname>Singletary</surname><given-names>E</given-names></name><name><surname>Sahin</surname><given-names>A</given-names></name><name><surname>McNeese</surname><given-names>MD</given-names></name></person-group><article-title>Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2005</year><volume>63</volume><fpage>1508</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">16169678</pub-id><pub-id pub-id-type="doi">10.1016/j.ijrobp.2005.05.044</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Recht</surname><given-names>A</given-names></name><name><surname>Pierce</surname><given-names>SM</given-names></name><name><surname>Abner</surname><given-names>A</given-names></name><name><surname>Vicini</surname><given-names>F</given-names></name><name><surname>Osteen</surname><given-names>RT</given-names></name><name><surname>Love</surname><given-names>SM</given-names></name><name><surname>Silver</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>JR</given-names></name></person-group><article-title>Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma</article-title><source>J Clin Oncol</source><year>1991</year><volume>9</volume><fpage>988</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">2033433</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suneson</surname><given-names>BL</given-names></name><name><surname>Lindholm</surname><given-names>C</given-names></name><name><surname>Hamrin</surname><given-names>E</given-names></name></person-group><article-title>Clinical incidence of lymphoedema in breast cancer patients in Jonkoping County, Sweden</article-title><source>Eur J Cancer Care (Engl)</source><year>1996</year><volume>5</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">8715464</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2354.1996.tb00199.x</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwan</surname><given-names>W</given-names></name><name><surname>Jackson</surname><given-names>J</given-names></name><name><surname>Weir</surname><given-names>LM</given-names></name><name><surname>Dingee</surname><given-names>C</given-names></name><name><surname>McGregor</surname><given-names>G</given-names></name><name><surname>Olivotto</surname><given-names>IA</given-names></name></person-group><article-title>Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>4242</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12377968</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2002.09.018</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urban</surname><given-names>JA</given-names></name><name><surname>Marjani</surname><given-names>MA</given-names></name></person-group><article-title>Significance of internal mammary lymph node metastases in breast cancer</article-title><source>Am J Roentgenol Radium Ther Nucl Med</source><year>1971</year><volume>111</volume><fpage>130</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">5540919</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>M</given-names></name><name><surname>Foster</surname><given-names>RS</given-names><suffix>Jr</suffix></name></person-group><article-title>Staging of breast cancer: a new rationale for internal mammary node biopsy</article-title><source>Arch Surg</source><year>1981</year><volume>116</volume><fpage>748</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">7016069</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><collab>Early Breast Cancer Trialists' Collaborative Group (EBCTCG)</collab></person-group><article-title>Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>1687</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">15894097</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(05)66544-0</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gianni</surname><given-names>L</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Eiermann</surname><given-names>W</given-names></name><name><surname>Guillem Porta</surname><given-names>V</given-names></name><name><surname>Semiglazov</surname><given-names>V</given-names></name><name><surname>Lluch</surname><given-names>A</given-names></name><name><surname>Zambetti</surname><given-names>M</given-names></name><name><surname>Sabadell</surname><given-names>D</given-names></name><name><surname>Raab</surname><given-names>G</given-names></name><name><surname>Llombart Cussac</surname><given-names>A</given-names></name><name><surname>Bozhok</surname><given-names>A</given-names></name><name><surname>Martinez-Agull&#x000f3;</surname><given-names>A</given-names></name><name><surname>Greco</surname><given-names>M</given-names></name><name><surname>Byakhov</surname><given-names>M</given-names></name><name><surname>Lopez Lopez</surname><given-names>JJ</given-names></name><name><surname>Mansutti</surname><given-names>M</given-names></name><name><surname>Valagussa</surname><given-names>P</given-names></name><name><surname>Bonadonna</surname><given-names>G</given-names></name><collab>European Cooperative Trial in Operable Breast Cancer Study Group</collab></person-group><article-title>Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>976</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">12637460</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2003.02.063</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Pienkowski</surname><given-names>T</given-names></name><name><surname>Mackey</surname><given-names>J</given-names></name><name><surname>Pawlicki</surname><given-names>M</given-names></name><name><surname>Guastalla</surname><given-names>JP</given-names></name><name><surname>Weaver</surname><given-names>C</given-names></name><name><surname>Tomiak</surname><given-names>E</given-names></name><name><surname>Al-Tweigeri</surname><given-names>T</given-names></name><name><surname>Chap</surname><given-names>L</given-names></name><name><surname>Juhos</surname><given-names>E</given-names></name><name><surname>Guevin</surname><given-names>R</given-names></name><name><surname>Howell</surname><given-names>A</given-names></name><name><surname>Fornander</surname><given-names>T</given-names></name><name><surname>Hainsworth</surname><given-names>J</given-names></name><name><surname>Coleman</surname><given-names>R</given-names></name><name><surname>Vinholes</surname><given-names>J</given-names></name><name><surname>Modiano</surname><given-names>M</given-names></name><name><surname>Pinter</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>SC</given-names></name><name><surname>Colwell</surname><given-names>B</given-names></name><name><surname>Prady</surname><given-names>C</given-names></name><name><surname>Provencher</surname><given-names>L</given-names></name><name><surname>Walde</surname><given-names>D</given-names></name><name><surname>Rodriguez-Lescure</surname><given-names>A</given-names></name><name><surname>Hugh</surname><given-names>J</given-names></name><name><surname>Loret</surname><given-names>C</given-names></name><name><surname>Rupin</surname><given-names>M</given-names></name><name><surname>Blitz</surname><given-names>S</given-names></name><name><surname>Jacobs</surname><given-names>P</given-names></name><name><surname>Murawsky</surname><given-names>M</given-names></name><name><surname>Riva</surname><given-names>A</given-names></name><name><surname>Vogel</surname><given-names>C</given-names></name><collab>Breast Cancer International Research Group 001 Investigators</collab></person-group><article-title>Adjuvant docetaxel for node-positive breast cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>2302</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">15930421</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa043681</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piccart-Gebhart</surname><given-names>MJ</given-names></name><name><surname>Procter</surname><given-names>M</given-names></name><name><surname>Leyland-Jones</surname><given-names>B</given-names></name><name><surname>Goldhirsch</surname><given-names>A</given-names></name><name><surname>Untch</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Gianni</surname><given-names>L</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Bell</surname><given-names>R</given-names></name><name><surname>Jackisch</surname><given-names>C</given-names></name><name><surname>Cameron</surname><given-names>D</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><name><surname>Steger</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>CS</given-names></name><name><surname>Andersson</surname><given-names>M</given-names></name><name><surname>Inbar</surname><given-names>M</given-names></name><name><surname>Lichinitser</surname><given-names>M</given-names></name><name><surname>L&#x000e1;ng</surname><given-names>I</given-names></name><name><surname>Nitz</surname><given-names>U</given-names></name><name><surname>Iwata</surname><given-names>H</given-names></name><name><surname>Thomssen</surname><given-names>C</given-names></name><name><surname>Lohrisch</surname><given-names>C</given-names></name><name><surname>Suter</surname><given-names>TM</given-names></name><name><surname>R&#x000fc;schoff</surname><given-names>J</given-names></name><name><surname>Suto</surname><given-names>T</given-names></name><name><surname>Greatorex</surname><given-names>V</given-names></name><name><surname>Ward</surname><given-names>C</given-names></name><name><surname>Straehle</surname><given-names>C</given-names></name><name><surname>McFadden</surname><given-names>E</given-names></name><name><surname>Dolci</surname><given-names>MS</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><collab>Herceptin Adjuvant (HERA) Trial Study Team</collab></person-group><article-title>Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>1659</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">16236737</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa052306</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Romond</surname><given-names>EH</given-names></name><name><surname>Perez</surname><given-names>EA</given-names></name><name><surname>Bryant</surname><given-names>J</given-names></name><name><surname>Suman</surname><given-names>VJ</given-names></name><name><surname>Geyer</surname><given-names>CE</given-names><suffix>Jr</suffix></name><name><surname>Davidson</surname><given-names>NE</given-names></name><name><surname>Tan-Chiu</surname><given-names>E</given-names></name><name><surname>Martino</surname><given-names>S</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Kaufman</surname><given-names>PA</given-names></name><name><surname>Swain</surname><given-names>SM</given-names></name><name><surname>Pisansky</surname><given-names>TM</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><name><surname>Kutteh</surname><given-names>LA</given-names></name><name><surname>Vogel</surname><given-names>VG</given-names></name><name><surname>Visscher</surname><given-names>DW</given-names></name><name><surname>Yothers</surname><given-names>G</given-names></name><name><surname>Jenkins</surname><given-names>RB</given-names></name><name><surname>Brown</surname><given-names>AM</given-names></name><name><surname>Dakhil</surname><given-names>SR</given-names></name><name><surname>Mamounas</surname><given-names>EP</given-names></name><name><surname>Lingle</surname><given-names>WL</given-names></name><name><surname>Klein</surname><given-names>PM</given-names></name><name><surname>Ingle</surname><given-names>JN</given-names></name><name><surname>Wolmark</surname><given-names>N</given-names></name></person-group><article-title>Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>1673</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">16236738</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa052122</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baum</surname><given-names>M</given-names></name><name><surname>Buzdar</surname><given-names>A</given-names></name><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Forbes</surname><given-names>J</given-names></name><name><surname>Houghton</surname><given-names>J</given-names></name><name><surname>Howell</surname><given-names>A</given-names></name><name><surname>Sahmoud</surname><given-names>T</given-names></name><collab>The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group</collab></person-group><article-title>Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses</article-title><source>Cancer</source><year>2003</year><volume>98</volume><fpage>1802</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">14584060</pub-id><pub-id pub-id-type="doi">10.1002/cncr.11745</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coombes</surname><given-names>RC</given-names></name><name><surname>Hall</surname><given-names>E</given-names></name><name><surname>Gibson</surname><given-names>LJ</given-names></name><name><surname>Paridaens</surname><given-names>R</given-names></name><name><surname>Jassem</surname><given-names>J</given-names></name><name><surname>Delozier</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>SE</given-names></name><name><surname>Alvarez</surname><given-names>I</given-names></name><name><surname>Bertelli</surname><given-names>G</given-names></name><name><surname>Ortmann</surname><given-names>O</given-names></name><name><surname>Coates</surname><given-names>AS</given-names></name><name><surname>Bajetta</surname><given-names>E</given-names></name><name><surname>Dodwell</surname><given-names>D</given-names></name><name><surname>Coleman</surname><given-names>RE</given-names></name><name><surname>Fallowfield</surname><given-names>LJ</given-names></name><name><surname>Mickiewicz</surname><given-names>E</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>L&#x000f8;nning</surname><given-names>PE</given-names></name><name><surname>Cocconi</surname><given-names>G</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Stuart</surname><given-names>N</given-names></name><name><surname>Snowdon</surname><given-names>CF</given-names></name><name><surname>Carpentieri</surname><given-names>M</given-names></name><name><surname>Massimini</surname><given-names>G</given-names></name><name><surname>Bliss</surname><given-names>JM</given-names></name><name><surname>Velde</surname><given-names>C van de</given-names></name><collab>Intergroup Exemestane Study</collab></person-group><article-title>A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>1081</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">15014181</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa040331</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goss</surname><given-names>PE</given-names></name><name><surname>Ingle</surname><given-names>JN</given-names></name><name><surname>Martino</surname><given-names>S</given-names></name><name><surname>Robert</surname><given-names>NJ</given-names></name><name><surname>Muss</surname><given-names>HB</given-names></name><name><surname>Piccart</surname><given-names>MJ</given-names></name><name><surname>Castiglione</surname><given-names>M</given-names></name><name><surname>Tu</surname><given-names>D</given-names></name><name><surname>Shepherd</surname><given-names>LE</given-names></name><name><surname>Pritchard</surname><given-names>KI</given-names></name><name><surname>Livingston</surname><given-names>RB</given-names></name><name><surname>Davidson</surname><given-names>NE</given-names></name><name><surname>Norton</surname><given-names>L</given-names></name><name><surname>Perez</surname><given-names>EA</given-names></name><name><surname>Abrams</surname><given-names>JS</given-names></name><name><surname>Therasse</surname><given-names>P</given-names></name><name><surname>Palmer</surname><given-names>MJ</given-names></name><name><surname>Pater</surname><given-names>JL</given-names></name></person-group><article-title>A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>1793</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">14551341</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa032312</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><collab>Breast International Group (BIG) 1&#x02013;98 Collaborative Group</collab><name><surname>Th&#x000fc;rlimann</surname><given-names>B</given-names></name><name><surname>Keshaviah</surname><given-names>A</given-names></name><name><surname>Coates</surname><given-names>AS</given-names></name><name><surname>Mouridsen</surname><given-names>H</given-names></name><name><surname>Mauriac</surname><given-names>L</given-names></name><name><surname>Forbes</surname><given-names>JF</given-names></name><name><surname>Paridaens</surname><given-names>R</given-names></name><name><surname>Castiglione-Gertsch</surname><given-names>M</given-names></name><name><surname>Gelber</surname><given-names>RD</given-names></name><name><surname>Rabaglio</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Wardley</surname><given-names>A</given-names></name><name><surname>Price</surname><given-names>KN</given-names></name><name><surname>Goldhirsch</surname><given-names>A</given-names></name></person-group><article-title>A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>2747</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16382061</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa052258</pub-id></citation></ref></ref-list></back></article>